Results 11 to 20 of about 174,020 (338)

Coagulation markers in patients with coronary artery disease

Journal of Biological Research, 2022
Coronary artery disease (CAD) is a major public health problem all over the world, and although diagnostic and treatment approaches are improving, the majority of individuals who suffer CAD will not survive.
Tetiana Marynenko, Tetiana Halenova, Nataliia Raksha, Tetiana Vovk, Yuliya Tyravska, Olexii Savchuk, Liudmyla Ostapchenko   +6 more
doaj   +1 more source

Assessing the individual roles of FII, FV, and FX activity in the thrombin generation process

Frontiers in Cardiovascular Medicine, 2022
Thrombin generation (TG) is known as a physiological approach to assess the hemostatic function. Although it correlates well with thrombosis and bleeding, in the current setup it is not sensitive to the effects of fluctuations in single coagulation ...
Cuicui Bai, Cuicui Bai, Joke Konings, Joke Konings, Marisa Ninivaggi, Marcus Lancé, Bas de Laat, Bas de Laat, Romy de Laat-Kremers   +8 more
doaj   +1 more source

How we treat bleeding associated with direct oral anticoagulants [PDF]

, 2016
Direct oral anticoagulants are at least as effective as vitamin K antagonists for the prevention and treatment of thromboembolism. Unfortunately, differently from vitamin K antagonists, they have the great drawback of lacking specific antidotes in the ...
Franchini, Massimo, Liumbruno, Giancarlo M, Marano, Giuseppe, Pupella, Simonetta, VAGLIO, Stefania   +4 more
core   +1 more source

Thrombophilic molecular markers in young patients (<40 years) with coronary artery disease

Indian Journal of Pathology and Microbiology, 2012
Background: There has been an alarming rise in the incidence of coronary artery disease (CAD) in India especially involving the age group of less than 45 years. In recent past, various studies focused on hemostatic aspects of CAD, but could not determine
Mingma Sherpa, Satendra Sharma, Rajnish Avasthi   +2 more
doaj   +1 more source

Prothrombin Is Responsible for the Lupus Cofactor Phenomenon in a Patient with Lupus Anticoagulant/Hypoprothrombinemia Syndrome

TH Open, 2020
Lupus anticoagulant is a misnomer as it is commonly associated with thromboembolic events. In few cases, the name retains its literal meaning when it characterizes patients with a bleeding disorder.
Vittorio Pengo, Lorena Zardo, Maria Grazia Cattini, Elisa Bison, Elena Pontara, Sara Altinier, Chunyan Cheng, Gentian Denas   +7 more
doaj   +1 more source

Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis [PDF]

, 2002
Hormone replacement therapy (HRT) increases the risk of venous thrombosis. We investigated whether this risk is affected by carriership of hereditary prothrombotic abnormalities.
A. Rumley, Anderson, Bloemenkamp, Daly, E. Daly, F. M. Helmerhorst, F. R. Rosendaal, G. D. O. Lowe, Grady, Grodstein, Hulley, Jick, Kniffin, Lowe, M. Vessey, M. Woodward, Mehta, Nordström, Oger, Rees, Rosendaal, Rosendaal, Silverstein, Stadel, Vandenbroucke, Vessey, Woolf   +26 more
core   +1 more source

NAFLD‐related hepatocellular carcinoma: The growing challenge

Hepatology, EarlyView., 2022
Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah, Rashmee Patil, Stephen A. Harrison   +2 more
wiley   +1 more source

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma

Hepatology, EarlyView., 2022
Steatotic HCC can be diagnosed by MRI and forms a pro‐tumor immune microenvironment with high expression of PD‐L1, M2 polarization of macrophages and activation of CAFs, which may be a good target for combined immunotherapy. Abstract Background and Aims Immunotherapy has become the standard‐of‐care treatment for hepatocellular carcinoma (HCC), but its ...
Hiroki Murai, Takahiro Kodama, Kazuki Maesaka, Shoichiro Tange, Daisuke Motooka, Yutaka Suzuki, Yasuyuki Shigematsu, Kentaro Inamura, Yoshihiro Mise, Akio Saiura, Yoshihiro Ono, Yu Takahashi, Yota Kawasaki, Satoshi Iino, Shogo Kobayashi, Masashi Idogawa, Takashi Tokino, Tomomi Hashidate‐Yoshida, Hideo Shindou, Masanori Miyazaki, Yasuharu Imai, Satoshi Tanaka, Eiji Mita, Kazuyoshi Ohkawa, Hayato Hikita, Ryotaro Sakamori, Tomohide Tatsumi, Hidetoshi Eguchi, Eiichi Morii, Tetsuo Takehara   +29 more
wiley   +1 more source

Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome

Frontiers in Immunology, 2020
BackgroundCritically ill patients with coronavirus disease 2019 (COVID-19) have a profound hypercoagulable state and often develop coagulopathy which leads to organ failure and death. Because of a prolonged activated partial-thromboplastin time (aPTT), a
Maria Orietta Borghi, Maria Orietta Borghi, Asmaa Beltagy, Asmaa Beltagy, Emirena Garrafa, Emirena Garrafa, Daniele Curreli, Germana Cecchini, Caterina Bodio, Claudia Grossi, Simonetta Blengino, Angela Tincani, Franco Franceschini, Laura Andreoli, Maria Grazia Lazzaroni, Silvia Piantoni, Stefania Masneri, Francesca Crisafulli, Duilio Brugnoni, Maria Lorenza Muiesan, Massimo Salvetti, Gianfranco Parati, Erminio Torresani, Michael Mahler, Francesca Heilbron, Francesca Pregnolato, Martino Pengo, Francesco Tedesco, Nicola Pozzi, Pier Luigi Meroni   +29 more
doaj   +1 more source

OPTIMIZATION OF THE EVALUATION METHOD OF THE PERFORMANCE OF THERAPY USING INDIRECT ACTION ANTICOAGULANTS [PDF]

Biotechnologia Acta, 2022
Aim. Treatment by indirect anticoagulants (vitamin K antagonists) requires a personalized approach for controlling the overall level of prothrombin and the accumulation of its decarboxylated forms.
D. S. Korolova, O. V. Hornytska, V. A. Deyev, V. I. Gryshchuk, T. M. Chernyshenko, T. M. Platonova, V. O. Chernyshenko   +6 more
doaj   +1 more source